{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T04:33:12Z","timestamp":1760243592396,"version":"build-2065373602"},"reference-count":37,"publisher":"MDPI AG","issue":"20","license":[{"start":{"date-parts":[[2022,10,17]],"date-time":"2022-10-17T00:00:00Z","timestamp":1665964800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA165076","P30DK084567","CA15083","P50CA210964"],"award-info":[{"award-number":["CA165076","P30DK084567","CA15083","P50CA210964"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Mayo Clinic Center for Cell Signaling in Gastroenterology","award":["CA165076","P30DK084567","CA15083","P50CA210964"],"award-info":[{"award-number":["CA165076","P30DK084567","CA15083","P50CA210964"]}]},{"name":"Mayo Clinic Cancer Center","award":["CA165076","P30DK084567","CA15083","P50CA210964"],"award-info":[{"award-number":["CA165076","P30DK084567","CA15083","P50CA210964"]}]},{"name":"Mayo Clinic SPORE in Hepatobiliary Cancer","award":["CA165076","P30DK084567","CA15083","P50CA210964"],"award-info":[{"award-number":["CA165076","P30DK084567","CA15083","P50CA210964"]}]},{"name":"Cholangiocarcinoma Foundation","award":["CA165076","P30DK084567","CA15083","P50CA210964"],"award-info":[{"award-number":["CA165076","P30DK084567","CA15083","P50CA210964"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Cholangiocarcinoma (CCA) is a highly lethal cancer arising from the biliary tract epithelium. The cancer biology of this neoplasm is not well understood. To date, only a few CCA cell lines have been reported, which were mostly developed from Asian patients. In this study, we report and characterize a new intrahepatic CCA cell line, LIV27, derived from a surgically resected tumor in a 67-year-old Caucasian woman with primary sclerosing cholangitis (PSC). LIV27 cells grow well in collagen-coated flasks or plates with a doubling time of 57.8 h at passage 14. LIV27 cells have high tumorigenicity in nude mice and stain positive for CK7 and CK19, markers that differentiate CCA from hepatocellular carcinoma. Karyotype analysis showed that LIV27 is aneuploid. We established a single-locus short tandem repeat profile for the LIV27 cell line. This newly established cell line will be a useful model for studying the molecular pathogenesis of, and developing novel therapies for, cholangiocarcinoma.<\/jats:p>","DOI":"10.3390\/cancers14205080","type":"journal-article","created":{"date-parts":[[2022,10,17]],"date-time":"2022-10-17T21:11:51Z","timestamp":1666041111000},"page":"5080","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Establishment and Characterization of a New Human Intrahepatic Cholangiocarcinoma Cell Line LIV27"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8280-2538","authenticated-orcid":false,"given":"Xiwei","family":"Ding","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing 210000, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kais","family":"Zakharia","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, University of Iowa, Iowa City, IA 52242, USA"},{"name":"Aurora St. Luke\u2019s Medical Center, GI Associates, Milwaukee, WI 53215, USA"},{"name":"Mayo Clinic and Mayo Clinic Cancer Center, Division of Gastroenterology and Hepatology, College of Medicine and Science, Rochester, MN 55905, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine D.","family":"Moser","sequence":"additional","affiliation":[{"name":"Mayo Clinic and Mayo Clinic Cancer Center, Division of Gastroenterology and Hepatology, College of Medicine and Science, Rochester, MN 55905, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3812-6747","authenticated-orcid":false,"given":"Nellie A.","family":"Campbell","sequence":"additional","affiliation":[{"name":"Mayo Clinic and Mayo Clinic Cancer Center, Division of Gastroenterology and Hepatology, College of Medicine and Science, Rochester, MN 55905, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunling","family":"Hu","sequence":"additional","affiliation":[{"name":"Mayo Clinic and Mayo Clinic Cancer Center, Division of Gastroenterology and Hepatology, College of Medicine and Science, Rochester, MN 55905, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nataliya","family":"Razumilava","sequence":"additional","affiliation":[{"name":"Mayo Clinic and Mayo Clinic Cancer Center, Division of Gastroenterology and Hepatology, College of Medicine and Science, Rochester, MN 55905, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roongruedee","family":"Chaiteerakij","sequence":"additional","affiliation":[{"name":"Mayo Clinic and Mayo Clinic Cancer Center, Division of Gastroenterology and Hepatology, College of Medicine and Science, Rochester, MN 55905, USA"},{"name":"Division of Gastroenterology, Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok 10330, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hassan M.","family":"Shaleh","sequence":"additional","affiliation":[{"name":"Mayo Clinic and Mayo Clinic Cancer Center, Division of Gastroenterology and Hepatology, College of Medicine and Science, Rochester, MN 55905, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia T.","family":"Greipp","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rondell P.","family":"Graham","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoping","family":"Zou","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing 210000, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vishal S.","family":"Chandan","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA"},{"name":"Department of Pathology and Laboratory Medicine, School of Medicine, University of California, Irvine, CA 92697, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7885-8574","authenticated-orcid":false,"given":"Lewis R.","family":"Roberts","sequence":"additional","affiliation":[{"name":"Mayo Clinic and Mayo Clinic Cancer Center, Division of Gastroenterology and Hepatology, College of Medicine and Science, Rochester, MN 55905, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,10,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1016\/S0140-6736(13)61903-0","article-title":"Cholangiocarcinoma","volume":"383","author":"Razumilava","year":"2014","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"236","DOI":"10.5009\/gnl17102","article-title":"Liver Fluke-Associated Biliary Tract Cancer","volume":"12","author":"Prueksapanich","year":"2018","journal-title":"Gut Liver"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","article-title":"Cholangiocarcinoma 2020: The next horizon in mechanisms and management","volume":"17","author":"Banales","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"109580","DOI":"10.1016\/j.cbi.2021.109580","article-title":"Dichloromethane increases mutagenic DNA damage and transformation ability in cholangiocytes and enhances metastatic potential in cholangiocarcinoma cell lines","volume":"346","author":"Buranarom","year":"2021","journal-title":"Chem. Biol. Interact"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.3109\/00365521.2011.589472","article-title":"Epidemiological trends in incidence and mortality of hepatobiliary cancers in Germany","volume":"46","author":"Ciesek","year":"2011","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1038\/ajg.2012.173","article-title":"Biliary tract cancers in Olmsted County, Minnesota, 1976\u20132008","volume":"107","author":"Yang","year":"2012","journal-title":"Am. J. Gastroenterol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1111\/liv.12325","article-title":"Incidence and mortality trends for biliary tract cancers in Austria","volume":"34","author":"Pinter","year":"2014","journal-title":"Liver Int."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1634\/theoncologist.2015-0446","article-title":"Forty-Year Trends in Cholangiocarcinoma Incidence in the U.S.: Intrahepatic Disease on the Rise","volume":"21","author":"Saha","year":"2016","journal-title":"Oncologist"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41572-021-00300-2","article-title":"Cholangiocarcinoma","volume":"9","author":"Brindley","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Borad, M.J., Champion, M.D., Egan, J.B., Liang, W.S., Fonseca, R., Bryce, A.H., McCullough, A.E., Barrett, M.T., Hunt, K., and Patel, M.D. (2014). Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma. PLoS Genet., 10.","DOI":"10.1371\/journal.pgen.1004135"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1158\/2159-8290.CD-17-0368","article-title":"Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma","volume":"7","author":"Jusakul","year":"2017","journal-title":"Cancer Discov."},{"key":"ref_12","first-page":"95","article-title":"Cholangiocarcinoma\u2014Evolving concepts and therapeutic strategies","volume":"15","author":"Rizvi","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S2468-1253(21)00196-5","article-title":"Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: Mature results from a multicentre, open-label, single-arm, phase 2 study","volume":"6","author":"Javle","year":"2021","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1200\/JCO.2017.75.5009","article-title":"Phase II Study of BGJ398 in Patients with FGFR-Altered Advanced Cholangiocarcinoma","volume":"36","author":"Javle","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.2217\/fon-2020-0299","article-title":"Infigratinib in patients with advanced cholangiocarcinoma with FGFR2 gene fusions\/translocations: The PROOF 301 trial","volume":"16","author":"Makawita","year":"2020","journal-title":"Future Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"417","DOI":"10.3389\/fonc.2019.00417","article-title":"Mutant Isocitrate Dehydrogenase Inhibitors as Targeted Cancer Therapeutics","volume":"9","author":"Golub","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/j.bbadis.2017.08.027","article-title":"Targeting cholangiocarcinoma","volume":"1864 (4 Pt B)","author":"Mertens","year":"2018","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jhep.2019.10.009","article-title":"Systemic therapies for intrahepatic cholangiocarcinoma","volume":"72","author":"Kelley","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.cld.2017.06.004","article-title":"Primary Sclerosing Cholangitis: What the Gastroenterologist and Hepatologist Needs to Know","volume":"21","author":"Gossard","year":"2017","journal-title":"Clin. Liver Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1111\/liv.13354","article-title":"An update on cancer risk and surveillance in primary sclerosing cholangitis","volume":"37","author":"Rodriguez","year":"2017","journal-title":"Liver Int."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1016\/j.cgh.2015.05.035","article-title":"Primary Sclerosing Cholangitis as a Premalignant Biliary Tract Disease: Surveillance and Management","volume":"13","author":"Rizvi","year":"2015","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_22","first-page":"1195","article-title":"Establishment and characterization of a human cholangiocarcinoma cell line","volume":"18","author":"Ma","year":"2007","journal-title":"Oncol. Rep."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/sj.bjc.6600440","article-title":"Establishment and characterisation of six human biliary tract cancer cell lines","volume":"87","author":"Ku","year":"2002","journal-title":"Br. J. Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1620\/tjem.177.61","article-title":"Establishment of a new extrahepatic bile duct carcinoma cell line, TFK-1","volume":"177","author":"Saijyo","year":"1995","journal-title":"Tohoku J. Exp. Med"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/S0168-8278(85)80002-7","article-title":"Biliary adenocarcinoma. Characterisation of three new human tumor cell lines","volume":"1","author":"Knuth","year":"1985","journal-title":"J. Hepatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1002\/1097-0142(19920401)69:7<1664::AID-CNCR2820690705>3.0.CO;2-P","article-title":"Establishment and characterization of a new human extrahepatic bile duct carcinoma cell line (KMBC)","volume":"69","author":"Yano","year":"1992","journal-title":"Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/BF02623562","article-title":"A new human cholangiocellular carcinoma cell line (HuCC-T1) producing carbohydrate antigen 19\/9 in serum-free medium","volume":"25","author":"Miyagiwa","year":"1989","journal-title":"In Vitro Cell Dev. Biol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1245\/s10434-019-07649-5","article-title":"Establishment and Characterization of Two Novel Cholangiocarcinoma Cell Lines","volume":"26","author":"Zhang","year":"2019","journal-title":"Ann. Surg. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/ijc.2910520217","article-title":"Two new human cholangiocarcinoma cell lines and their cytogenetics and responses to growth factors, hormones, cytokines or immunologic effector cells","volume":"52","author":"Shimizu","year":"1992","journal-title":"Int. J. Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s005340070038","article-title":"Establishment and characterization of human hilar bile duct carcinoma cell line and cell strain","volume":"7","author":"Jiao","year":"2000","journal-title":"J. Hepato-Biliary-Pancreat Surg."},{"key":"ref_31","first-page":"29","article-title":"Establishment and characterization of the human cholangiocarcinoma cell line HChol-Y1 in a serum-free, chemically defined medium","volume":"75","author":"Yamaguchi","year":"1985","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/BF01851205","article-title":"Establishment and characterization of a cell line from a human cholangiocellular carcinoma","volume":"188","author":"Kusaka","year":"1988","journal-title":"Res. Exp. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.3748\/wjg.v11.i22.3392","article-title":"Establishment and characterization of an opisthorchiasis-associated cholangiocarcinoma cell line (KKU-100)","volume":"11","author":"Sripa","year":"2005","journal-title":"World J. Gastroenterol."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Huang, Y., Liu, Y., Zheng, C., and Shen, C. (2017). Investigation of Cross-Contamination and Misidentification of 278 Widely Used Tumor Cell Lines. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0170384"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"8012","DOI":"10.1073\/pnas.121616198","article-title":"Short tandem repeat profiling provides an international reference standard for human cell lines","volume":"98","author":"Masters","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.tranon.2018.09.005","article-title":"Preclinical In Vitro and In Vivo Evidence of an Antitumor Effect of CX-4945, a Casein Kinase II Inhibitor, in Cholangiocarcinoma","volume":"12","author":"Zakharia","year":"2019","journal-title":"Transl. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"20080","DOI":"10.18632\/oncotarget.7914","article-title":"Antitumor effect of the novel sphingosine kinase 2 inhibitor ABC294640 is enhanced by inhibition of autophagy and by sorafenib in human cholangiocarcinoma cells","volume":"7","author":"Ding","year":"2016","journal-title":"Oncotarget"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/20\/5080\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:55:50Z","timestamp":1760144150000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/20\/5080"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,17]]},"references-count":37,"journal-issue":{"issue":"20","published-online":{"date-parts":[[2022,10]]}},"alternative-id":["cancers14205080"],"URL":"https:\/\/doi.org\/10.3390\/cancers14205080","relation":{},"ISSN":["2072-6694"],"issn-type":[{"type":"electronic","value":"2072-6694"}],"subject":[],"published":{"date-parts":[[2022,10,17]]}}}